# Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OA

> **NCT04097379** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 45 (actual)

## Conditions studied

- Osteoarthritis (OA)

## Interventions

- **DRUG:** LRX712
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04097379
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-20
- **Primary completion:** 2024-08-08
- **Final completion:** 2025-01-17
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04097379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04097379, "Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OA". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04097379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*